Travere Therapeutics (NASDAQ:TVTX) just reported results for the first quarter of 2024.
- Travere Therapeutics reported earnings per share of -$1.51. This was below the analyst estimate for EPS of -99 cents.
- The company reported revenue of $41.37 million.
- This was 3.44% worse than the analyst estimate for revenue of $42.85 million.